natgillin/translations-raw huggingface dataset:
No pharmacokinetic interaction was observed between oral rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers.
U ispitivanjima na zdravim dobrovoljcima nije zapažena farmakokinetička interakcija između oralnog rivastigmina i digoksina, varfarina, diazepama ili fluoksetina.
There have been rare post-marketing reports of patients experiencing disseminated skin hypersensitivity reactions when administered rivastigmine irrespective of the route of administration (oral, transdermal).
Poslije stavljanja lijeka u promet, zabilježene su rijetke pojave diseminirane reakcije kožne preosjetljivosti u bolesnika kod primjene rivastigmina, neovisno o putu primjene (peroralno, transdermalno).
Patients and their caregivers must be instructed on important administration instructions for Rivastigmine 3M Health Care Ltd. transdermal patch (see section 4.2).
Bolesnici i njihovi njegovatelji moraju dobiti važne upute o primjeni Rivastigmin 3M Health Care Ltd. transdermalnog flastera (vidjeti dio 4.2).
How to remove your Rivastigmine 3M Health Care Ltd. transdermal patch Gently pull at one edge of the patch to remove it slowly from the skin.
Kako skinuti Rivastigmin 3M Health Care Ltd. transdermalni flaster Lagano povucite jedan kraj flastera kako biste ga polako skinuli s kože.
Each patch is sealed in a pouch that protects it until you are ready to put it on. Do not open the pouch or remove a patch until just before you apply it.
Svaki je flaster zapakiran u vrećicu koja ga štiti do trenutka kada ste spremni postaviti ga.
- Only wear one Rivastigmine 3M Health Care Ltd. patch at a time and replace the patch with a new one after 24 hours.
Potrebno je primijeniti samo jedan Rivastigmin 3M Health Care Ltd. flaster koji ćete zamijeniti novim flasterom nakon 24 sata.
SPECIAL STORAGE CONDITIONS Store in the original package in order to protect from light.
POSEBNE MJERE ČUVANJA Čuvati u originalnom pakiranju radi zaštite od svjetlosti.
Slow heartbeat and fainting may also occur.
Također može doći do usporenih otkucaja srca i nesvjestice.
If you have to undergo surgery whilst using Rivastigmine 3M Health Care Ltd. transdermal patches, tell your doctor that you are using them because they may exaggerate the effects of some muscle relaxants during anaesthesia.
Ako se, tijekom primjene Rivastigmin 3M Health Care Ltd. transdermalnih flastera, morate podvrgnuti operaciji obavijestite svog liječnika da ih koristite jer oni mogu tijekom anestezije pojačati učinke
Very rare (may affect up to 1 in 10,000 people) - High blood pressure - Inflammation of the pancreas - the signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting) - Bleeding in the gut - shows as blood in stools or when being sick - Seeing things that are not there (hallucinations) - Some people who have been violently sick have had tearing of the tube that connects your mouth with your stomach (oesophagus)
Vrlo rijetko (mogu se javiti u do 1 na 10 000 ljudi) - Upala gušterače - znakovi uključuju jaku bol u gornjem dijelu trbuha, često s osjećajem - Krvarenje u crijevu - prikazuje se kao krv u stolici ili kada povraćate - U nekih je bolesnika koji su imali izrazitu mučninu došlo do pucanja cijevi koja povezuje Vaša
How to apply your Rivastigmine 3M Health Care Ltd. transdermal patch Rivastigmine 3M Health Care Ltd. patches are transparent to translucent, plastic patches that stick to the skin.
Kako staviti Rivastigmin 3M Health Care Ltd. transdermalni flaster Rivastigmin 3M Health Care Ltd. flasteri su prozirni do zamućeni, plastični flasteri koji se lijepe na kožu.
After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit.
Nakon najmanje četiri tjedna liječenja te ako se lijek prema mišljenju liječnika dobro podnosi, dozu od 4,6 mg/24 h potrebno je povećati na 9,5 mg/24 h, dnevnu preporučenu djelotvornu dozu, s kojom treba nastaviti dokle god bolesnik od toga ima terapijsku korist.
Store in the original package in order to protect from light.
Čuvati u originalnom pakiranju radi zaštite od svjetlosti.
Do not use Rivastigmine 3M Health Care Ltd. - if you are allergic to rivastigmine or any of the other ingredients of this medicine (listed in section 6).
- Ako ste alergični na rivastigmin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
Dehydration
Možete dehidrirati
If you use more Rivastigmine 3M Health Care Ltd. than you should If you accidentally apply more than one patch, remove all the patches from your skin, then inform your doctor that you have accidentally applied more than one patch.
Ako ste zabunom stavili više od jednog flastera, skinite sve flastere sa svoje kože i obavijestite liječnika da ste slučajno stavili više od jednog flastera.
If the oral dose of 9 mg/day has not been stable and well tolerated, a switch to 4.6 mg/24 h transdermal patches is recommended.
Ako oralna doza od 9 mg/dan nije bila stabilna i nije se dobro podnosila, preporučuje se prebacivanje na transdermalni flaster u dozi od
After switching to 4.6 mg/24 h transdermal patches, provided these are well tolerated after a minimum of four weeks of treatment, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, which is the recommended effective dose.
Nakon prijelaza na transdermalni flaster u dozi od 4,6 mg/24 h, pod uvjetom da se dobro podnosi nakon najmanje četiri tjedna liječenja, dozu od 4,6 mg/24 h potrebno je povećati na 9,5 mg/24 h, što je
Rivastigmine 13.3 mg/24 h N = 265
Rivastigmin 13,3 mg/24 h N=265
The fluctuation index (FI), a measure of the relative difference between peak and trough concentrations ((Cmax-Cmin)/Cavg), was 0.58 for rivastigmine 4.6 mg/24 h transdermal patches, 0.77 for rivastigmine 9.5 mg/24 h transdermal patches and 0.72 for rivastigmine 13.3 mg/24 h transdermal patches, thus demonstrating a much smaller fluctuation between trough and peak concentrations than for the oral formulation (FI = 3.96 (6 mg/day) and 4.15 (12 mg/day)).
Indeks fluktuacije (FI), mjera relativne razlike između vršne i najniže koncentracije ((Cmax-Cmin)/Cavg), bio je 0,58 za transdermalne flastere s 4,6 mg/24 h rivastigmina, 0,77 za transdermalne flastere s 9,5 mg/24 h rivastigmina i 0,72 za transdermalne flastere s 13,3 mg/24 h rivastigmina, čime se potvrđuje puno manja fluktuacija između najniže i vršne koncentracije nego kod oralne formulacije (FI = 3,96 (6 mg/dan) i 4,15 (12 mg/dan)).
Therefore, in patients with dementia treated with rivastigmine, the ability to continue driving or operating complex machines should be routinely evaluated by the treating physician.
Zbog toga u bolesnika s demencijom, koji se liječe rivastigminom, liječnik treba rutinski procjenjivati mogu li nastaviti upravljati vozilima ili raditi sa složenim strojevima.
Patients involved in the placebo-controlled study had an MMSE (Mini-Mental State Examination) score of 10-20.
MiniMental State Examination - Skraćeni pregled mentalnog stanja) od 10-20.
The increase in prothrombin time induced by warfarin is not affected by administration of oral rivastigmine.
Primjena oralnog rivastigmina ne utječe na povećanje protrombinskog vremena koje inducira varfarin.
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones.
Farmakoterapijska skupina: psihoanaleptici, antikolinesteraze, ATK oznaka: N06DA03 Rivastigmin je inhibitor acetilkolinesteraze i butirilkolinesteraze karbamatnog tipa, za kojeg se smatra da olakšava kolinergičku neurotransmisiju usporavanjem razgradnje acetilkolina kojeg otpuštaju funkcionalno intaktni kolinergički neuroni.
Can you wear your Rivastigmine 3M Health Care Ltd. transdermal patch when you are bathing, swimming, or in the sun?
Možete li nositi Rivastigmin 3M Health Care Ltd. transdermalni flaster dok se kupate, plivate ili - Kupanje, plivanje ili tuširanje ne bi trebalo utjecati na flaster.
Make sure the patch does not loosen during these activities.
Pazite da se flaster ne odlijepi
After oral administration, the Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects.
Nakon oralne primjene, Cmax rivastigmina bio je oko 60% veći, a AUC rivastigmina bila je više nego dvostruko veća u ispitanika s blagim do umjerenim oštećenjem jetre, nego u zdravih
What you need to know before you use Rivastigmine 3M Health Care Ltd.
Što morate znati prije nego počnete primjenjivati Rivastigmin 3M Health Care Ltd.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan transdermalni flaster oslobađa 4,6 mg rivastigmina u 24 sata.
Not known (frequency cannot be estimated from the available data) - Allergic reaction where the patch was used, such as blisters or inflamed skin - The signs of Parkinson's disease get worse - such as tremor, stiffness and shuffling - Inflammation of the pancreas - signs include serious upper stomach pain, often with feeling sick
Nepoznato (učestalost nuspojava ne može se procijeniti iz dostupnih podataka) - Alergijska reakcija na mjestu primjene flastera, kao što su mjehurići ili upala kože - Pogoršanje znakova Parkinsonove bolesti - kao što su nevoljno drhtanje, ukočenost i poteškoće pri kretanju
- if you have gastrointestinal reactions such as feeling sick (nausea), being sick (vomiting) and diarrhoea.
- ako imate probavne reakcije poput osjećaja mučnine, povraćanje i proljeva.
Special populations: - Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions (see section 4.2).
- Bolesnici s tjelesnom težinom manjom od 50 kg mogu imati više nuspojava te je vjerojatnije da će prekinuti liječenje zbog nuspojava (vidjeti dio 4.2).
Rectangular patches, approximately 3.5 cm by 2.6 cm with rounded corners.
Pravokutni flasteri zaobljenih kuteva, približnih dimenzija 3,5 cm s 2,6 cm.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan transdermalni flaster oslobađa 9,5 mg rivastigmina u 24 sata.
Each patch consists of a combination of a removable, transparent, split release liner, a functional layer containing drug-inadhesive (DIA) matrix, and a protective backing layer.
Jedan transdermalni flaster sastoji se od sljedeće kombinacije: odvojive, transparentne zaštitne folije koja se može skinuti, funkcionalnog sloja koji sadrži lijek u adhezivnom matriksu i zaštitnog potpornog sloja.
*A marketing authorisation for Rivastigmine 3M Health Care Ltd. 13.3 mg/24 h transdermal patch is currently not available, this presentation may although be available from other marketing authorisation holders.
13,3 mg/24 h trenutno nije dostupno, iako ova doza može biti dostupna od drugih nositelja odobrenja.
- Do not use this medicine after the expiry date, which is stated on the carton and pouch after
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i vrećici iza Rok valjanosti/EXP.
Initial dose Treatment is started with 4.6 mg/24 h.
Početna doza Liječenje se započinje dozom od 4,6 mg/24 h.
No specific interaction studies have been performed with Rivastigmine 3M Health Care Ltd. transdermal patches.
Nisu provedena specifična ispitivanja interakcija s Rivastigmin 3M Health Care Ltd. transdermalnim flasterima.
To prevent interference with the adhesive properties of the transdermal patch, no cream, lotion or powder should be applied to the skin area where the medicinal product is to be applied.
Radi sprječavanja ometanja ljepljivih svojstava transdermalnog flastera, na površinu kože na koju će se primijeniti lijek ne smije se nanositi krema, losion ili puder.
LIST OF EXCIPIENTS Also contains polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate.
Također sadrži poliester, etilvinilacetat, ljepilo od akrilatnog kopolimera i izopropil miristat.
• Instructions to provide patients and caregivers with the patient reminder card The patient reminder card should contain the following key messages:
• Upute o davanju kartice s podsjetnikom za bolesnika bolesnicima i njegovateljima
Each transdermal patch of 8.3 cm2 contains 14.33 mg of rivastigmine.
Jadan transdermalni flaster površine 8,3 cm2 sadrži 14,33 mg rivastigmina.
- The other ingredients are polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate.
Drugi sastojci su poliester, etilvinilacetat, ljepilo od akrilatnog kopolimera i izopropil miristat.
For patients starting treatment for the first time and for patients restarting Rivastigmine 3M Health Care Ltd. after treatment interruption, please begin with the second picture.
Za bolesnike koji po prvi put počinju liječenje i za bolesnike koji ponovno počinju primjenjivati Rivastigmin 3M Health Care Ltd.
Each transdermal patch of 4.15 cm2 contains 7.17 mg of rivastigmine.
Jadan transdermalni flaster površine 4,15 cm2 sadrži 7,17 mg rivastigmina.
Patients involved in the active comparator controlled study had an initial baseline MMSE score of 10-24.
48-tjedno aktivno kontrolirano ispitivanje s komparatorom Bolesnici uključeni u aktivno kontrolirano ispitivanje s komparatorom imali su početni rezultat na MMSE-u od 10-24.
Otherwise treatment should be re-initiated with 4.6 mg/24 h.
U suprotnom, liječenje treba ponovno započeti pri dozi od 4,6 mg/24 h.
Polyester and ethyl vinyl acetate
Potporni sloj: poliester i etilvinilacetat
If you are pregnant, the benefits of using Rivastigmine 3M Health Care Ltd. transdermal patches must be assessed against the possible effects on your unborn child. Rivastigmine 3M Health Care Ltd. should not be used during pregnancy unless clearly necessary.
Ako ste trudni, potrebno je ocijeniti koristi od uporabe Rivastigmin 3M Health Care Ltd. transdermalnih flastera u usporedbi s mogućim učincima na Vaše nerođeno dijete.
In case the adhesive residue is left over on your skin, gently soak the area with warm water and mild soap or use baby oil to remove it. Alcohol or other dissolving liquids (nail polish remover or other solvents) should not be used.
Ako Vam je na koži ostalo nešto ljepila, lagano natopite površinu toplom vodom i blagim sapunom ili ga skinite uljem za bebe.
Rivastigmine should not be used during pregnancy unless clearly necessary.
Rivastigmin 3M Health Care Ltd. treba izbjegavati tijekom trudnoće, osim ako njegova primjena nije doista nužna.
- Hepatic impairment: Patients with clinically significant hepatic impairment might experience more adverse reactions (see sections 4.2 and 5.2).
- Oštećenje bubrega: Bolesnici s klinički značajnim oštećenjem bubrega mogli bi osjetiti više nuspojava (vidjeti dio 4.2 i 5.2).
transdermal patches 9.5 mg/24 h
Transdermalni flasteri s rivastigminom 9,5 mg/24 h
Each transdermal patch consists of three layers; a backing layer, an adhesive layer containing the medicine and a transparent, split release liner.
Jedan transdermalni flaster sastoji se od tri sloja: potpornog sloja, ljepljivog sloja koji sadrži lijek i prozirne zaštitne folije koja se može skinuti.
Hepatitis, elevated liver function tests Skin and subcutaneous tissue disorders Common Not known
Hepatitis, povišeni rezultati testova funkcije jetre
Rivastigmine 13.3 mg/24 h
Rivastigmin 13,3 mg/24 h
They may experience more adverse reactions and may be more likely to discontinue due to adverse reactions.
Mogli bi osjetiti više nuspojava te uslijed toga biti skloniji prekidu liječenja zbog
Mean baseline  SD
Srednja početna vrijednost  SD
What Rivastigmine 3M Health Care Ltd. looks like and contents of the pack The transdermal patches are rectangular with rounded corners, approximately 2.5 cm by 1.8 cm (Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch) or 3.5 cm by 2.6 cm (Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch).
Kako Rivastigmin 3M Health Care Ltd. izgleda i sadržaj pakiranja Flasteri su pravokutnog oblika, zaobljenih kuteva, približnih dimenzija 2,5 cm s 1,8 cm (Rivastigmin 3M Health Care Ltd.
• Press the patch firmly in place for at least 30 seconds using the palm of the hand.
• Držite flaster dlanom pritisnut na mjestu najmanje 30 sekundi.
There is no relevant use of Rivastigmine 3M Health Care Ltd. in the paediatric population in the treatment of Alzheimer's disease.
Nema relevantne primjene Rivastigmina 3M Health Care Ltd. u pedijatrijskoj populaciji u liječenju
However, use of rivastigmine patch may lead to allergic contact dermatitis.
Prethodna anamneza reakcija na mjestu primjene, koje ukazuju na alergijski kontaktni dermatitis s
- Carefully remove any existing patch before putting on a new one.
- Pažljivo uklonite postojeći flaster (ako ga imate) prije stavljanja novoga.
Other adverse reactions Care must be taken when prescribing Rivastigmine 3M Health Care Ltd. transdermal patches:
Druge nuspojave Potreban je oprez kod propisivanja Rivastigmin 3M Health Care Ltd. transdermalnih flastera:
The most commonly reported skin irritation events during the first 24 weeks of the double-blind period with rivastigmine 13.3 mg/24 h transdermal patches and rivastigmine 9.5 mg/24 h transdermal patches, respectively were application site erythema (5.7% vs 4.6%) and application site pruritus (3.6% vs 2.8%).
Najučestalije prijavljeni događaji nadražaja kože tijekom prva 24 tjedna dvostruko slijepog razdoblja s transdermalnim flasterima s rivastigminom u dozi od 13,3 mg/24 h i u dozi od 9,5 mg/24 h bili su eritem na mjestu primjene (5,7% za prvi u odnosu na 4,6% za drugi) te pruritus na mjestu primjene (3,6% za prvi u odnosu na 2,8% za drugi).
Where to apply your Rivastigmine 3M Health Care Ltd. transdermal patch - Before you apply a patch, make sure that your skin is clean, dry and hairless, free of any powder, oil, moisturiser or lotion that could keep the patch from sticking to your skin properly, free of cuts, rashes and/or irritations.
Gdje treba postaviti Rivastigmin 3M Health Care Ltd. transdermalni flaster - Prije postavljanja flastera provjerite da Vam je koža čista, suha i bez dlaka, bez pudera, ulja,
STATEMENT OF ACTIVE SUBSTANCE(S) 1 transdermal patch of 4.15 cm2 contains 7.17 mg rivastigmine and delivers 4.6 mg/24 h.
1 transdermalni flaster površine 4,15 cm2 sadrži 7,17 mg rivastigmina i oslobađa 4,6 mg/24 h.
Rivastigmine 4.6 mg/24 h
4,6 mg/24 h.
Other medicines and Rivastigmine 3M Health Care Ltd.
Drugi lijekovi i Rivastigmin 3M Health Care Ltd.
STATEMENT OF ACTIVE SUBSTANCE(S) 1 transdermal patch of 8.3 cm2 contains 14.33 mg rivastigmine and delivers 9.5 mg/24 h.
1 transdermalni flaster površine 8,3 cm2 sadrži 14,33 mg rivastigmina i oslobađa 9,5 mg/24 h.
No study was conducted with rivastigmine transdermal patches in subjects with hepatic impairment.
Nije provedeno nikakvo ispitivanje s transdermalnim flasterima s rivastigminom u ispitanika s oštećenjem bubrega.
You should not breast-feed during treatment with Rivastigmine 3M Health Care Ltd. transdermal patches.
Ne smijete dojiti tijekom liječenja Rivastigmin 3M Health Care Ltd. transdermalnim flasterima.
9.5 mg/24 h transdermal patches.
9,5 mg/24 h transdermalni flaster
- Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patches: Each patch releases 9.5 mg of rivastigmine per 24 hours, is 8.3 cm2 and contains 14.33 mg of rivastigmine.
9,5 mg/24 h transdermalni flasteri: Jedan flaster koji oslobađa 9,5 mg rivastigmina tijekom 24 sata ima površinu 8,3 cm2 i sadrži 14,33 mg
Rivastigmine capsules 12 mg/day N = 256
12 mg/dan N=256
If you forget to use Rivastigmine 3M Health Care Ltd.
Ako ste zaboravili primijeniti Rivastigmin 3M Health Care Ltd.
Application site skin reactions (e.g. application site erythema, application site pruritus, application site oedema, application site dermatitis, application site irritation), asthenic conditions (e.g. fatigue,
Kožne reakcije na mjestu primjene (npr. eritem na mjestu primjene, pruritus na mjestu primjene, edem na mjestu primjene, dermatitis na mjestu primjene, nadražaj na mjestu primjene), astenična stanja (npr. umor i astenija), pireksija, gubitak tjelesne težine
Switching from capsules or oral solution to transdermal patches Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with rivastigmine capsules or oral solution can be switched to Rivastigmine 3M Health Care Ltd. transdermal patches as follows: - A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Na temelju usporedive izloženosti oralnom i transdermalnom rivastigminu (vidjeti dio 5.2), bolesnici liječeni kapsulama ili oralnom otopinom s rivastigminom mogu prijeći na Rivastigmin3M Health Care
The percentages decreased in both rivastigmine 13.3 mg/24 h transdermal patch and rivastigmine 9.5 mg/24 h transdermal patch treatment groups over time (>24 weeks): application site erythema (0.8% vs. 1.6%) and application site pruritus (0.4% vs. 1.2%), respectively.
Postotci su se tijekom vremena (>24 tjedna) smanjili i u terapijskoj skupini koja je primjenjivala transdermalni flaster s rivastigminom u dozi od 13,3 mg/24 h i u onoj koja je primjenjivala transdermalni flaster s rivastigminom u dozi od 9,5 mg/24 h: eritem na mjestu primjene (0,8% u odnosu na 1,6%) i pruritus na mjestu primjene (0,4% u odnosu na 1,2%).
Rivastigmine 9.5 mg/24 h
9,5 mg/24 h
- Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patches: Each patch releases 4.6 mg of rivastigmine per 24 hours, is 4.15 cm2 and contains 7.17 mg of rivastigmine.
4,6 mg/24 h transdermalni flasteri: Jedan flaster koji oslobađa 4,6 mg rivastigmina tijekom 24 sata ima površinu 4,15 cm2 i sadrži 7,17 mg
- A patient on a dose of 12 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches.
- Bolesnik na stabilnoj dozi od 9 mg/dan oralnog rivastigmina koju dobro podnosi može prijeći na transdermalni flaster u dozi od 9,5 mg/24 h.
The active substance of Rivastigmine 3M Health Care Ltd. is rivastigmine.
Djelatna tvar Rivastigmina 3M Health Care Ltd. je rivastigmin.
Dose escalation
Povećavanje doze
Name and address of the manufacturer responsible for batch release
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet
Take off the previous patch before putting ONE new patch on.
Ukloniti prethodni flaster prije postavljanja JEDNOG novog flastera.
- The patch should be pressed down firmly for at least 30 seconds using the palm of the hand until the edges stick well.
Odjednom se smije nositi samo jedan flaster (vidjeti - Flaster treba držati čvrsto pritisnut dlanom najmanje 30 sekundi dok se rubovi dobro ne zalijepe.
• Summary of Product Characteristics
• Sažetak opisa svojstava lijeka
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1 transdermal patch per pouch.
SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA
- if you have, or have ever had, difficulties in passing urine.
- ako imate ili ste imali otežano mokrenje.
Other side effects seen with Rivastigmine 3M Health Care Ltd. capsules or oral solution and which may occur with the patch:
Ostale nuspojave zabilježene uz primjenu Rivastigmin 3M Health Care Ltd. kapsula ili oralne
Hands should be washed with soap and water after removing the patch.
Nakon uklanjanja flastera, ruke treba oprati vodom i sapunom.
Uncommon (may affect up to 1 in 100 people) - Uneven heart rate (e.g. fast heart rate) - Difficulty sleeping - Accidental falls
- Inkontinencija mokraće (nemogućnost zadržavanja mokraće) Manje često (mogu se javiti u do 1 na 100 ljudi) - Problemi s radom srca, poput ubrzanih ili usporenih otkucaja srca
Psychiatric disorders Common
Infekcija urinarnog trakta
IMPORTANT: - Take off the previous patch before putting ONE new patch on. - Only one patch per day.
VAŽNO: - Uklonite prethodni flaster prije stavljanja JEDNOG novog flastera.